ITeos Therapeutics, Inc.
100.00%
10,000
1808865
46565G104
Aug 28, 2025
Sep 3, 2025, 04:15 PM
Reporting Persons (8)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| TANG CAPITAL PARTNERS, LP | Partnership | 100.00% | 10,000 | 0 | 10,000 |
| KEVIN TANG | Individual | 100.00% | 10,000 | 0 | 10,000 |
| CONCENTRA BIOSCIENCES, LLC | Other | 100.00% | 10,000 | 0 | 10,000 |
| TANG CAPITAL MANAGEMENT, LLC | Other | 100.00% | 10,000 | 0 | 10,000 |
| CONCENTRA MERGER SUB VIII, INC | CO | 0.00% | 0 | 0 | 0 |
| TANG CAPITAL PARTNERS INTERNATIONAL, LP | Partnership | 0.00% | 0 | 0 | 0 |
| TANG CAPITAL PARTNERS III, INC | CO | 0.00% | 0 | 0 | 0 |
| TANG CAPITAL PARTNERS IV, INC | CO | 0.00% | 0 | 0 | 0 |
Disclosure Items (4)
Common Stock, par value $0.001 per share
ITeos Therapeutics, Inc.
321 Arsenal Street, Watertown, MA, 02472
The information previously provided in response to Item 5 is hereby amended and restated by replacing the text thereof in its entirety with the following: The information set forth in the cover pages of this Schedule 13D is hereby incorporated by reference into this Item 5. As of the date hereof the Reporting Persons beneficially own an aggregate of 10,000 shares of the Issuer's Common Stock, representing 100% of the outstanding shares.
See item 5(a) above.
Except as described in this Amendment No. 2, there have been no transactions in the Issuer's Common Stock during the past 60 days by the Reporting Persons.
No person other than a Reporting Person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock beneficially owned by the Reporting Persons.
Not applicable.
Exhibit 1: Joint Filing Agreement by and among the Reporting Persons (filed as Exhibit 1 of the 13D filed on June 12, 2025 by the Reporting Persons with respect to the Common Stock of the Issuer). Exhibit 2: Schedule A: Transactions during the past 60 days (filed as Exhibit 2 of the 13D filed on June 12, 2025 by the Reporting Persons with respect to the Common Stock of the Issuer). Exhibit 3: Agreement and Plan of Merger, dated as of July 18, 2025, by and among iTeos Therapeutics, Inc., Concentra Biosciences, LLC, and Concentra Merger Sub VIII, Inc. (filed as Exhibit 2.1 of the Issuer's Current Report filed on Form 8-K on July 21, 2025). Exhibit 4: Schedule TO (filed by Concentra on August 1, 2025). Exhibit 5: Offer to Purchase, dated August 1, 2025 (filed as Exhibit (a)(1)(A) to the Schedule TO filed by Concentra on August 1, 2025). Exhibit 6: Form of Letter of Transmittal (filed as Exhibit (a)(1)(B) to the Schedule TO filed by Concentra on August 1, 2025). Exhibit 7: Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (filed as Exhibit (a)(1)(C) to the Schedule TO filed by Concentra on August 1, 2025). Exhibit 8: Form of Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (filed as Exhibit (a)(1)(D) to the Schedule TO filed by Concentra on August 1, 2025). Exhibit 9: Confidentiality Agreement, dated June 10, 2025, between iTeos and TCM (filed as Exhibit (d)(2) to the Schedule TO filed by Concentra on August 1, 2025). Exhibit 10: Limited Guaranty, dated July 18, 2025 (filed as Exhibit (d)(3) to the Schedule TO filed by Concentra on August 1, 2025). Exhibit 11: Joint Filing Agreement, dated September 3, 2025, by and among the Reporting Persons.